χ2 association for CXCL9 levels above the median with cGVHD
| . | Total number per group (cGVHD %) . | P value* . | |
|---|---|---|---|
| Less than or equal to median . | More than median . | ||
| UM validation | 64 (20%) | 45 (71%) | <.001 |
| Newly diagnosed FHCRC | 58 (60%) | 61 (84%) | .001 |
| Established FHCRC | 71 (68%) | 54 (81%) | .04 |
| . | Total number per group (cGVHD %) . | P value* . | |
|---|---|---|---|
| Less than or equal to median . | More than median . | ||
| UM validation | 64 (20%) | 45 (71%) | <.001 |
| Newly diagnosed FHCRC | 58 (60%) | 61 (84%) | .001 |
| Established FHCRC | 71 (68%) | 54 (81%) | .04 |
CI, confidence interval.
Adjusted for age, stem cell source (bone marrow/cord blood vs peripheral blood), HLA match (matched sibling vs other), and diagnosis (malignant vs nonmalignant).